Loading
Gyre Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$746.5M
No insider purchase over the last 90 days. The latest was filed 10 Aug 2022.
Gyre Therapeutics, Inc.: what insiders have been doing
Gyre Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Gyre Therapeutics, Inc. logged 8 filings by 1 insider.
Only sales appear on the open market, 4 sales in all totalling €39k, filed by 1 insider. The totals do not cover 2 filings with an undisclosed amount. One trade stands out by size: a sale of €21k from Ye Weiguo, disclosed on 27 May 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 8 filings, this issuer sits below that mark. Our records for Gyre Therapeutics, Inc. go back to 2021, with 6 purchases and 45 sales on the open market in total.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
86
Thresholds
n/a
Buy Volume
€12,345
6 ops. · all time
Sell Volume
€771,487
45 ops. · all time
Who traded when
BuySaleSongjiang Ma41 sales
Weiguo Ye4 sales
Since the insiders bought
- +92.9%Entry US$85.00 · Close at T+365 US$164.00
- +67.9%Entry US$112.00 · Close at T+365 US$188.00
- +67.9%Entry US$112.00 · Close at T+365 US$188.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,126 of 24,148 companies
43.7
score / 100
Value25
Quality63
FCF yld-0.1%
Earn yld0.7%
EV/EBITDA53.3x
ROE-17%
Gross mgn95%
Net mgn4.3%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.04
Analyst consensus
3 analysts1.00/5
US$18.00Target US$18.67(+165%)US$20.00
Income statement
RevenueUS$116.6M
Gross profitUS$111.2M95% margin
EBITDAUS$14M12% margin
Net incomeUS$5M-19.3% margin
Valuation
P/Book6.9x
Beta4.74
Balance sheet & cash
Market capUS$746.5M
Total debtUS$939k
Free Cash Flow-US$913k
Debt / Equity2%
Profitability & ownership
ROE-17.4%
ROA-5.4%
% insiders74.4%
% institutions8.2%
Last declaration on 11 June 2026
Declarations86 total
2,000 shares@ US$10.282.5% of flowCommon StockSEC:0001140361-25-020754:0
558 shares@ US$10.070.7% of flowCommon StockSEC:0001140361-25-020754:1
2,000 shares@ US$10.972.7% of flowCommon StockSEC:0001140361-25-020474:0
182 shares@ US$10.240.2% of flowCommon StockSEC:0001140361-25-020474:1
2,000 shares@ US$11.252.7% of flowCommon StockSEC:0001140361-25-020156:0
2,000 shares@ US$11.312.8% of flowCommon StockSEC:0001140361-25-019893:0
20 shares@ US$11.300.0% of flowCommon StockSEC:0001140361-25-019468:0
2,000 shares@ US$10.562.6% of flowCommon StockSEC:0001140361-25-018927:0
15,000 shares@ US$6.93100.0% of flowCommon StockSEC:0001140361-25-014601:0
174 shares@ US$10.000.2% of flowCommon StockSEC:0001140361-25-010234:0
2,000 shares@ US$10.132.5% of flowCommon StockSEC:0001140361-25-009877:0
2,000 shares@ US$12.093.0% of flowCommon StockSEC:0001140361-25-009424:0
2,000 shares@ US$11.803.0% of flowCommon StockSEC:0001140361-25-009017:0
2,000 shares@ US$11.402.9% of flowCommon StockSEC:0001140361-25-008623:0
53 shares@ US$13.030.1% of flowCommon StockSEC:0001140361-25-008091:0
25 of 86 declarations
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a company focused on developing innovative treatments for neurodegenerative diseases. It is listed on NASDAQ under the ticker GYRE.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
